Roche's obinutuzumab wins EU committee backing for a third autoimmune indication, lupus

Roche is a step closer to widening the European use of obinutuzumab, sold as Gazyvaro in the EU and Gazyva in the US. On 13 November 2026 the company said the EMA's human-medicines committee, the CHMP, had issued a positive opinion for systemic lupus erythematosus (SLE).

The opinion covers adults whose lupus is active at a moderate or severe level, who test positive for disease-related autoantibodies and whose condition has not been brought under control by standard treatment. Roche expects the European Commission to rule soon. That ruling is the legally binding step that normally follows a CHMP endorsement and is what actually allows EU sales for the new use.

The regulatory track runs in parallel in the US, where Roche says the FDA has accepted its supplemental biologics licence application for SLE. The drug already carries a lupus nephritis approval in more than 65 countries, plus an idiopathic nephrotic syndrome approval in the US, so SLE would add a further autoimmune use to the label.

The information released does not include pricing, sales projections or a launch timetable, so the commercial weight of the lupus indication cannot yet be sized from the announcement alone.